Emmaus Life Sciences, Inc. (EMMA) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE, CA 90503 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,389 | 2,547 | 2,021 | 2,279 | 2,487 | 29,698 | |||
| Cash and cash equivalent | 1,389 | 2,547 | 2,021 | 2,279 | 2,487 | 1,769 | |||
| Short-term investments | 27,929 | ||||||||
| Receivables | 2,623 | 5,524 | 375 | 1,040 | 198 | 2,150 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,635 | 1,711 | 2,379 | 4,392 | 7,087 | 7,971 | |||
| Inventory | 1,635 | 1,711 | 2,379 | 4,392 | 7,087 | 7,971 | |||
| Prepaid expense | 272 | 536 | 467 | 326 | 388 | 735 | |||
| Other current assets | 226 | 596 | 449 | 394 | 1,097 | 667 | |||
| Other undisclosed current assets | 622 | 595 | 598 | 660 | |||||
| Total current assets: | 6,767 | 11,509 | 6,289 | 9,091 | 11,257 | 41,221 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,530 | 2,337 | 2,799 | 3,485 | 4,072 | 4,474 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 46 | 59 | 75 | 147 | 120 | 151 | |||
| Long-term investments and receivables | 18,828 | 17,616 | |||||||
| Long-term investments | 18,828 | 17,616 | |||||||
| Other noncurrent assets | 222 | 296 | 263 | 295 | 296 | 285 | |||
| Other undisclosed noncurrent assets | 15,037 | 20,978 | 19,971 | 26,100 | 43,791 | 13,325 | |||
| Total noncurrent assets: | 16,835 | 23,670 | 41,936 | 47,643 | 48,279 | 18,235 | |||
| TOTAL ASSETS: | 23,602 | 35,179 | 48,225 | 56,734 | 59,536 | 59,456 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 16,926 | 17,725 | 13,549 | 9,189 | 7,460 | 11,498 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 579 | 627 | 991 | ||
| Accounts payable | 5,175 | 5,887 | 3,785 | 2,583 | 2,023 | 7,277 | |||
| Accrued liabilities | 7,732 | 8,174 | 7,239 | 5,936 | 4,769 | 3,188 | |||
| Other undisclosed accounts payable and accrued liabilities | 4,019 | 3,664 | 2,525 | 91 | 41 | 42 | |||
| Debt | 17,014 | 16,383 | 14,655 | 1,200 | 6,280 | 11,601 | |||
| Derivative instruments and hedges, liabilities | 8 | 65 | 70 | 1,503 | 1,071 | 38 | |||
| Other liabilities | 16,557 | 14,681 | 12,917 | 4,404 | 2,706 | 5,748 | |||
| Due to related parties | ✕ | ✕ | ✕ | 2,367 | 800 | ||||
| Other undisclosed current liabilities | 13,050 | 12,653 | 10,765 | 20,004 | 5,865 | 3,942 | |||
| Total current liabilities: | 63,555 | 61,507 | 54,323 | 37,100 | 23,382 | 32,827 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 4,061 | 6,620 | 3,932 | ||||||
| Long-term debt, excluding current maturities | 800 | 3,150 | |||||||
| Liabilities, other than long-term debt | 14,280 | 19,202 | 27,613 | 33,173 | 34,470 | 33,750 | |||
| Due to related parties | ✕ | ✕ | ✕ | 3,346 | |||||
| Other liabilities | 13,465 | 17,363 | 21,714 | 33,173 | 34,470 | 33,750 | |||
| Operating lease, liability | 815 | 1,839 | 2,553 | 3,261 | 3,470 | 3,932 | |||
| Other undisclosed noncurrent liabilities | 2,246 | 2,226 | 380 | 3,850 | 222 | ||||
| Total noncurrent liabilities: | 16,526 | 21,428 | 27,993 | 41,084 | 41,312 | 37,682 | |||
| Total liabilities: | 80,081 | 82,935 | 82,316 | 78,184 | 64,694 | 70,509 | |||
| Equity | |||||||||
| Equity, attributable to parent | (56,479) | (47,756) | (34,091) | (21,450) | (5,158) | (11,053) | |||
| Common stock | 64 | 62 | 50 | 49 | 49 | 48 | |||
| Additional paid in capital | 225,896 | 225,333 | 220,815 | 220,022 | 218,728 | 215,207 | |||
| Accumulated other comprehensive income (loss) | (2,995) | (160) | (2,619) | (255) | 1,144 | (79) | |||
| Accumulated deficit | (262,575) | (256,122) | (252,337) | (241,266) | (225,079) | (226,229) | |||
| Receivable from shareholders or affiliates for issuance of capital stock | (16,869) | (16,869) | |||||||
| Total equity: | (56,479) | (47,756) | (34,091) | (21,450) | (5,158) | (11,053) | |||
| TOTAL LIABILITIES AND EQUITY: | 23,602 | 35,179 | 48,225 | 56,734 | 59,536 | 59,456 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 16,653 | 29,597 | 18,390 | 20,610 | 23,167 | 22,752 | ||
| Gain (loss) on disposition of assets for financial service operations | 7,672 | (21,432) | ||||||
| Realized investment losses | (21,947) | |||||||
| Cost of revenue | (1,201) | (1,342) | (2,588) | (3,312) | (2,248) | (1,094) | ||
| Gross profit: | 15,452 | 28,255 | 15,802 | 17,298 | 20,919 | 21,658 | ||
| Operating expenses | (17,346) | (24,715) | (22,388) | (23,426) | (20,951) | (26,170) | ||
| Operating income (loss): | (1,894) | 3,540 | (6,586) | (6,128) | (32) | (4,512) | ||
| Nonoperating income (expense) (Gain (Loss), Foreign Currency Transaction, before Tax) | (148) | (1,767) | (2,662) | (2,017) | ||||
| Interest and debt expense | 1,032 | (8,204) | (5,514) | (3,466) | (7,414) | (31,404) | ||
| Loss from continuing operations before equity method investments, income taxes: | (1,010) | (6,431) | (14,762) | (11,611) | (7,446) | (35,916) | ||
| Loss from equity method investments | (1,713) | (1,913) | (2,733) | (2,060) | (414) | |||
| Other undisclosed income (loss) from continuing operations before income taxes | (5,414) | 4,352 | 6,110 | (1,577) | 10,479 | (18,348) | ||
| Income (loss) from continuing operations before income taxes: | (6,424) | (3,792) | (10,565) | (15,921) | 973 | (54,678) | ||
| Income tax expense (benefit) | (29) | 59 | (60) | (25) | 381 | (164) | ||
| Income (loss) from continuing operations: | (6,453) | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (15,946) | 1,354 | (54,842) | |
| Net income (loss) available to common stockholders, diluted: | (6,453) | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (6,453) | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | ||
| Other comprehensive income (loss) | (2,835) | 2,459 | (2,364) | (1,399) | 1,223 | (10) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (9,288) | (1,274) | (12,989) | (17,345) | 2,577 | (54,852) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.